In recent years the problem of relationship between young age and breast cancer growth attracts particular attention of researchers and still takes a special place in modern oncology. The value of this problem is significantly increased in our days, as observed the increased rate of breast cancer in women of active fertile age.
The study included 180 young women with unfavorable prognostic factors: edematous-infiltrative forms, multicentric tumor growth, angiolymphatic invasion, 3-grade tumor. All patients underwent immunohistochemical investigation with the study of ER, PR, HER2 / neu HER2 / neu, Ki67, VEGF.
During the research the following results have been obtained: 53% of patients have no oncoprotein HER2 / neu-, 22% of patients with HER2 / neu +, 10% of patients with HER2 / neu ++ , 15% of patients with HER2 / neu +++. On receptor status examination we revealed ER- and PE- in 71% of patients, while 47% of patients had ER + and PR +. In the study of vascular endothelial growth factor VEGF we determined that VEGF- was in 32% of patients, and 66% of patients were with VEGF +. We examined the relationship of vascular endothelial factor VEGF with oncoprotein HER2 / neu. As a result, we found that in group of patients with VEGF- HER2 / neu- was in 37% of patients, HER2 / neu + in 29%, HER2 / neu ++ in 19% of patients, HER2 / neu +++ in 15% of patients. In group of patients with VEGF +, HER2 / neu- was in 32% of patients, HER2 / neu + in 29% of patients, HER2 / neu ++ in 22% of patients, HER2 / neu ++ + in 17% of patients, respectively. When studied proliferative activity Ki67 we revealed that 55.6% patients had Ki-67> 25% and 44.3% of patients had Ki-67 <25%.
Lack of estrogen and progesterone receptors on the surface of tumor cells is characterized by a high-grade tumor and aggressive course of the disease. The maximum expression of NER-2neu in breast cancer cells is an independent predictor of the clinical course of the disease and is associated with high metastatic potential. The phenotype of breast cancer that characterized by a number of adverse factors ER-, PR-, NER-2neu-, have more aggressive malignant course and an unfavorable prognosis in terms of clinical course and response to specific treatment.
Clinical trial identification
All authors have declared no conflicts of interest.